The Municipal Health Department of Ribeirão Preto, São Paulo, has initiated a program to offer Nirsevimab, an antibody that provides immediate protection against the respiratory syncytial virus (RSV) for vulnerable infants and children. This initiative will provide ongoing support throughout the year, focusing mainly on premature newborns and young children with pre-existing health conditions, which place them at a higher risk of respiratory complications.

The administration of this immunobiological product specifically targets premature infants born at or before 36 weeks and six days of gestation, as well as children up to 23 months old with comorbidities. Infants will receive this treatment while still hospitalized in neonatal intensive care units within the SUS (Unified Health System) or at the UBDS Castelo Branco health unit. This proactive approach aims to mitigate the health risks posed by RSV, particularly during the cold months when respiratory illnesses are more prevalent.

Luzia Márcia Romanholi, the Deputy Secretary of Health Surveillance, clarified that Nirsevimab is not a vaccine but rather a ready-to-use antibody that offers immediate protection for the infants. Although it may be colloquially referred to as a vaccine, its distinction lies in providing prompt immunity against RSV, crucial for newborns in their delicate early stages of life where health is precarious. The implementation of this treatment underlines a significant step in public health efforts to safeguard the health of the most vulnerable populations in Ribeirão Preto.